secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001140361-24-001849
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics cuts FY24 revenue guidance to $320-325M; Q2 revenue $79.1M, Auryon sales up 12.9%
--------------------------------------------------------------------------------

- FY24 revenue guidance lowered to $320M-$325M from $328M-$333M; adjusted EPS loss widens to ($0.35)-($0.42) from ($0.28)-($0.34).
- Q2 FY24 pro forma revenue $79.1M, growth 2.7%; Med Tech +3.5%, Auryon sales $11.4M (+12.9% YoY).
- PRESERVE (NanoKnife) and APEX AV (AlphaVac PE) studies fully enrolled; FDA submission for PE planned early 2024.
- Cumulative Auryon sales exceeded $100M; CE Mark for Auryon and AlphaVac expected 1H 2024.
- Full-year adjusted EPS profitability expected in FY27; manufacturing restructuring to fully outsourced model initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124001849/0001140361-24-001849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000114036124001849/ef20018682_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-001849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer